Ty Kiser
Concepts (439)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 13 | 2022 | 548 | 2.990 |
Why?
| Anti-Bacterial Agents | 15 | 2024 | 1465 | 2.580 |
Why?
| Teicoplanin | 3 | 2024 | 17 | 2.320 |
Why?
| Heparin | 10 | 2019 | 225 | 2.130 |
Why?
| Venous Thromboembolism | 5 | 2022 | 231 | 2.100 |
Why?
| Vancomycin | 6 | 2024 | 73 | 1.980 |
Why?
| Thrombocytopenia | 9 | 2020 | 175 | 1.970 |
Why?
| Hirudins | 8 | 2020 | 46 | 1.930 |
Why?
| Critical Illness | 19 | 2022 | 653 | 1.860 |
Why?
| Voriconazole | 3 | 2019 | 22 | 1.680 |
Why?
| Peptide Fragments | 7 | 2020 | 652 | 1.610 |
Why?
| Triazoles | 3 | 2019 | 123 | 1.570 |
Why?
| Antithrombins | 4 | 2020 | 49 | 1.560 |
Why?
| Peritonitis | 2 | 2024 | 75 | 1.520 |
Why?
| Intensive Care Units | 18 | 2022 | 620 | 1.440 |
Why?
| Peritoneal Dialysis | 2 | 2024 | 87 | 1.430 |
Why?
| Hemofiltration | 4 | 2017 | 31 | 1.350 |
Why?
| Thrombosis | 4 | 2021 | 293 | 1.340 |
Why?
| Thrombin | 3 | 2020 | 129 | 1.310 |
Why?
| Drug Packaging | 3 | 2016 | 42 | 1.310 |
Why?
| Antifungal Agents | 4 | 2021 | 125 | 1.240 |
Why?
| Thromboembolism | 3 | 2021 | 92 | 1.160 |
Why?
| Fibrinolytic Agents | 4 | 2018 | 230 | 1.140 |
Why?
| Pipecolic Acids | 4 | 2020 | 23 | 1.130 |
Why?
| Pulmonary Embolism | 3 | 2019 | 181 | 1.100 |
Why?
| Microbial Sensitivity Tests | 6 | 2021 | 298 | 1.100 |
Why?
| Tissue Plasminogen Activator | 2 | 2018 | 204 | 1.090 |
Why?
| Factor Xa Inhibitors | 2 | 2018 | 138 | 1.050 |
Why?
| Kidney Diseases | 5 | 2021 | 348 | 1.020 |
Why?
| Middle Aged | 48 | 2022 | 26552 | 0.990 |
Why?
| beta-Cyclodextrins | 2 | 2015 | 27 | 0.970 |
Why?
| Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 902 | 0.940 |
Why?
| Hospitalization | 7 | 2023 | 1765 | 0.900 |
Why?
| Retrospective Studies | 33 | 2023 | 12504 | 0.890 |
Why?
| Syringes | 3 | 2016 | 41 | 0.870 |
Why?
| Renal Replacement Therapy | 4 | 2022 | 69 | 0.870 |
Why?
| Humans | 91 | 2024 | 113531 | 0.840 |
Why?
| Aged | 33 | 2024 | 18944 | 0.840 |
Why?
| Invasive Fungal Infections | 2 | 2021 | 10 | 0.830 |
Why?
| Factor Xa | 2 | 2021 | 32 | 0.810 |
Why?
| Dalteparin | 2 | 2020 | 9 | 0.790 |
Why?
| Drug Stability | 4 | 2016 | 149 | 0.780 |
Why?
| Drug Monitoring | 4 | 2017 | 184 | 0.770 |
Why?
| Recombinant Proteins | 10 | 2021 | 1214 | 0.760 |
Why?
| Nephrologists | 1 | 2021 | 13 | 0.750 |
Why?
| Gram-Positive Bacterial Infections | 2 | 2020 | 60 | 0.750 |
Why?
| Partial Thromboplastin Time | 5 | 2014 | 50 | 0.750 |
Why?
| Hospital Mortality | 5 | 2020 | 780 | 0.740 |
Why?
| Adult | 36 | 2024 | 30245 | 0.740 |
Why?
| Atrial Fibrillation | 2 | 2022 | 325 | 0.740 |
Why?
| Adrenal Cortex Hormones | 2 | 2015 | 488 | 0.730 |
Why?
| Female | 51 | 2024 | 59115 | 0.720 |
Why?
| Male | 51 | 2021 | 55112 | 0.710 |
Why?
| Blood Coagulation Tests | 3 | 2016 | 51 | 0.710 |
Why?
| Kidney Failure, Chronic | 3 | 2020 | 490 | 0.690 |
Why?
| Dose-Response Relationship, Drug | 11 | 2019 | 1822 | 0.690 |
Why?
| Pseudomonas Infections | 2 | 2013 | 183 | 0.690 |
Why?
| Gram-Positive Bacteria | 1 | 2020 | 45 | 0.680 |
Why?
| Antiviral Agents | 3 | 2020 | 635 | 0.660 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 14 | 0.660 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2021 | 152 | 0.650 |
Why?
| Obesity, Morbid | 1 | 2022 | 197 | 0.640 |
Why?
| Diabetic Ketoacidosis | 1 | 2021 | 161 | 0.640 |
Why?
| Cold Temperature | 2 | 2016 | 125 | 0.630 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2018 | 27 | 0.620 |
Why?
| Macrolides | 1 | 2019 | 56 | 0.620 |
Why?
| Hemorrhage | 6 | 2022 | 599 | 0.610 |
Why?
| Nitriles | 1 | 2019 | 149 | 0.610 |
Why?
| Critical Care | 10 | 2021 | 474 | 0.600 |
Why?
| Dexmedetomidine | 4 | 2014 | 45 | 0.600 |
Why?
| Pulmonary Ventilation | 1 | 2018 | 66 | 0.600 |
Why?
| Glomerular Filtration Rate | 1 | 2021 | 605 | 0.600 |
Why?
| Anticonvulsants | 2 | 2017 | 176 | 0.590 |
Why?
| Treatment Outcome | 19 | 2022 | 9006 | 0.590 |
Why?
| Blood Transfusion | 2 | 2020 | 265 | 0.590 |
Why?
| Lung Transplantation | 3 | 2020 | 241 | 0.580 |
Why?
| Hepatorenal Syndrome | 2 | 2009 | 14 | 0.580 |
Why?
| Piracetam | 1 | 2017 | 14 | 0.560 |
Why?
| Ribavirin | 2 | 2020 | 89 | 0.550 |
Why?
| Neoplasms | 3 | 2020 | 2082 | 0.550 |
Why?
| Glass | 1 | 2016 | 42 | 0.540 |
Why?
| Intracranial Hemorrhages | 1 | 2017 | 74 | 0.540 |
Why?
| Hypnotics and Sedatives | 4 | 2014 | 133 | 0.540 |
Why?
| Thiocyanates | 1 | 2016 | 29 | 0.530 |
Why?
| Nitroprusside | 1 | 2016 | 64 | 0.530 |
Why?
| Thiosulfates | 1 | 2016 | 19 | 0.530 |
Why?
| Freezing | 1 | 2016 | 83 | 0.520 |
Why?
| Curriculum | 2 | 2021 | 803 | 0.520 |
Why?
| Aged, 80 and over | 13 | 2022 | 6296 | 0.510 |
Why?
| Infusions, Intravenous | 6 | 2020 | 368 | 0.510 |
Why?
| Cyclodextrins | 1 | 2015 | 7 | 0.500 |
Why?
| Pyridines | 1 | 2019 | 417 | 0.500 |
Why?
| Cardiopulmonary Bypass | 2 | 2016 | 173 | 0.500 |
Why?
| Cerebral Hemorrhage | 1 | 2016 | 97 | 0.490 |
Why?
| Kidney | 2 | 2021 | 1179 | 0.490 |
Why?
| Vasodilator Agents | 2 | 2016 | 303 | 0.490 |
Why?
| Dronabinol | 1 | 2016 | 118 | 0.480 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.480 |
Why?
| Antidotes | 1 | 2016 | 135 | 0.470 |
Why?
| Stroke | 2 | 2022 | 1016 | 0.470 |
Why?
| Cohort Studies | 14 | 2021 | 4880 | 0.460 |
Why?
| Vasoconstriction | 2 | 2023 | 174 | 0.450 |
Why?
| Osmotic Pressure | 1 | 2014 | 28 | 0.450 |
Why?
| Methylprednisolone | 1 | 2014 | 80 | 0.440 |
Why?
| Respiratory Insufficiency | 3 | 2022 | 285 | 0.420 |
Why?
| Multivariate Analysis | 5 | 2017 | 1421 | 0.400 |
Why?
| Arginine | 4 | 2020 | 235 | 0.400 |
Why?
| Pneumonia, Bacterial | 1 | 2013 | 102 | 0.390 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 371 | 0.390 |
Why?
| Administration, Oral | 4 | 2022 | 719 | 0.390 |
Why?
| Ganciclovir | 1 | 2012 | 48 | 0.390 |
Why?
| Pseudomonas aeruginosa | 2 | 2013 | 297 | 0.390 |
Why?
| Pharmacy | 2 | 2021 | 28 | 0.370 |
Why?
| Acute Kidney Injury | 4 | 2018 | 676 | 0.370 |
Why?
| Pharmacies | 2 | 2021 | 32 | 0.370 |
Why?
| Substance Withdrawal Syndrome | 3 | 2022 | 159 | 0.370 |
Why?
| Empirical Research | 1 | 2011 | 21 | 0.360 |
Why?
| Nomograms | 1 | 2011 | 41 | 0.360 |
Why?
| Academic Medical Centers | 3 | 2019 | 406 | 0.350 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 19 | 0.350 |
Why?
| Sulfonamides | 4 | 2020 | 442 | 0.340 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 175 | 0.340 |
Why?
| Time Factors | 7 | 2018 | 6032 | 0.340 |
Why?
| Burns | 2 | 2018 | 232 | 0.330 |
Why?
| Drug Therapy, Combination | 5 | 2021 | 944 | 0.310 |
Why?
| Students, Pharmacy | 2 | 2021 | 97 | 0.300 |
Why?
| Patient Discharge | 3 | 2018 | 770 | 0.290 |
Why?
| Rivaroxaban | 2 | 2022 | 211 | 0.290 |
Why?
| Thrombin Time | 2 | 2020 | 11 | 0.290 |
Why?
| Daptomycin | 2 | 2021 | 17 | 0.290 |
Why?
| Polypropylenes | 1 | 2007 | 14 | 0.280 |
Why?
| Administration, Intravenous | 3 | 2017 | 122 | 0.280 |
Why?
| Sympathomimetics | 1 | 2007 | 25 | 0.280 |
Why?
| Phenylephrine | 1 | 2007 | 71 | 0.280 |
Why?
| Shock, Septic | 2 | 2022 | 185 | 0.280 |
Why?
| Expectorants | 1 | 2007 | 24 | 0.280 |
Why?
| Pharmacoepidemiology | 2 | 2019 | 20 | 0.270 |
Why?
| Prospective Studies | 7 | 2022 | 6189 | 0.270 |
Why?
| Drug Storage | 3 | 2016 | 57 | 0.270 |
Why?
| Anesthetics | 1 | 2007 | 54 | 0.270 |
Why?
| Drug Compounding | 2 | 2017 | 89 | 0.270 |
Why?
| Lorazepam | 3 | 2014 | 23 | 0.270 |
Why?
| Levofloxacin | 1 | 2006 | 22 | 0.260 |
Why?
| Ofloxacin | 1 | 2006 | 22 | 0.260 |
Why?
| Alcoholism | 2 | 2023 | 704 | 0.260 |
Why?
| Models, Biological | 1 | 2013 | 1589 | 0.260 |
Why?
| Respiration | 1 | 2007 | 168 | 0.260 |
Why?
| Acetylcysteine | 1 | 2007 | 141 | 0.260 |
Why?
| Pneumonia | 3 | 2023 | 561 | 0.260 |
Why?
| Young Adult | 8 | 2019 | 10400 | 0.260 |
Why?
| Gentamicins | 2 | 2023 | 42 | 0.260 |
Why?
| Area Under Curve | 4 | 2019 | 271 | 0.250 |
Why?
| Vasoconstrictor Agents | 2 | 2023 | 113 | 0.250 |
Why?
| Arginine Vasopressin | 1 | 2005 | 42 | 0.250 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2021 | 3252 | 0.250 |
Why?
| Length of Stay | 4 | 2019 | 963 | 0.250 |
Why?
| Octreotide | 1 | 2005 | 25 | 0.240 |
Why?
| Cross-Over Studies | 2 | 2020 | 432 | 0.240 |
Why?
| Neuromuscular Blocking Agents | 2 | 2018 | 23 | 0.240 |
Why?
| Warfarin | 2 | 2022 | 136 | 0.230 |
Why?
| Temperature | 3 | 2016 | 557 | 0.230 |
Why?
| Pharmacists | 4 | 2021 | 231 | 0.220 |
Why?
| Hydrogen-Ion Concentration | 2 | 2016 | 502 | 0.220 |
Why?
| Blood Coagulation | 2 | 2016 | 200 | 0.220 |
Why?
| Risk Factors | 7 | 2023 | 8606 | 0.220 |
Why?
| Liver Diseases | 1 | 2006 | 254 | 0.210 |
Why?
| Adolescent | 9 | 2022 | 17724 | 0.210 |
Why?
| Incidence | 2 | 2020 | 2310 | 0.210 |
Why?
| Saline Solution, Hypertonic | 1 | 2023 | 39 | 0.210 |
Why?
| Ethanol | 3 | 2022 | 532 | 0.210 |
Why?
| Liver Transplantation | 1 | 2009 | 693 | 0.210 |
Why?
| Thinness | 1 | 2022 | 87 | 0.190 |
Why?
| Sexual Harassment | 1 | 2021 | 25 | 0.190 |
Why?
| Aspergillosis | 1 | 2021 | 22 | 0.180 |
Why?
| Statistics, Nonparametric | 3 | 2017 | 384 | 0.180 |
Why?
| Candidiasis | 1 | 2021 | 51 | 0.180 |
Why?
| Prothrombin | 1 | 2021 | 22 | 0.180 |
Why?
| Cephalosporins | 1 | 2021 | 26 | 0.180 |
Why?
| Community Pharmacy Services | 1 | 2021 | 42 | 0.180 |
Why?
| Drug Administration Schedule | 3 | 2018 | 712 | 0.180 |
Why?
| Pharmaceutical Services | 1 | 2021 | 76 | 0.180 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2016 | 463 | 0.180 |
Why?
| Ascitic Fluid | 1 | 2020 | 13 | 0.170 |
Why?
| Vasoplegia | 1 | 2020 | 2 | 0.170 |
Why?
| Salvage Therapy | 1 | 2021 | 125 | 0.170 |
Why?
| Noninvasive Ventilation | 1 | 2020 | 31 | 0.170 |
Why?
| Platelet Count | 1 | 2020 | 78 | 0.170 |
Why?
| Monte Carlo Method | 2 | 2013 | 136 | 0.170 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 238 | 0.170 |
Why?
| Hydroxocobalamin | 1 | 2020 | 26 | 0.170 |
Why?
| Anti-Infective Agents | 1 | 2022 | 218 | 0.160 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2020 | 97 | 0.160 |
Why?
| Body Weight | 2 | 2021 | 853 | 0.160 |
Why?
| Speech Therapy | 1 | 2019 | 21 | 0.160 |
Why?
| Asthma | 2 | 2022 | 2016 | 0.160 |
Why?
| Intubation, Intratracheal | 1 | 2020 | 216 | 0.150 |
Why?
| Kidney Transplantation | 2 | 2018 | 537 | 0.150 |
Why?
| Hemostasis | 1 | 2019 | 64 | 0.150 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 192 | 0.150 |
Why?
| Logistic Models | 3 | 2017 | 1832 | 0.150 |
Why?
| Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| Atracurium | 1 | 2018 | 13 | 0.150 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 21 | 0.150 |
Why?
| Heart Failure, Systolic | 1 | 2018 | 21 | 0.150 |
Why?
| Coronary Circulation | 1 | 2018 | 131 | 0.150 |
Why?
| Gastric Emptying | 2 | 2008 | 39 | 0.150 |
Why?
| Calcineurin Inhibitors | 1 | 2018 | 57 | 0.150 |
Why?
| Cardiologists | 1 | 2018 | 40 | 0.150 |
Why?
| Occupational Therapy | 1 | 2019 | 74 | 0.150 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 131 | 0.150 |
Why?
| Gastrointestinal Agents | 2 | 2008 | 60 | 0.140 |
Why?
| Antibodies, Bacterial | 1 | 2018 | 119 | 0.140 |
Why?
| Immunotherapy | 1 | 2021 | 472 | 0.140 |
Why?
| Polyneuropathies | 1 | 2017 | 50 | 0.140 |
Why?
| Education, Pharmacy, Graduate | 1 | 2017 | 18 | 0.140 |
Why?
| Immunity, Humoral | 1 | 2018 | 112 | 0.140 |
Why?
| Databases, Factual | 2 | 2019 | 1127 | 0.140 |
Why?
| Self-Directed Learning as Topic | 1 | 2017 | 3 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 654 | 0.140 |
Why?
| Propensity Score | 2 | 2017 | 225 | 0.140 |
Why?
| Disease-Free Survival | 1 | 2018 | 617 | 0.140 |
Why?
| Pneumococcal Vaccines | 1 | 2018 | 131 | 0.140 |
Why?
| Pharmaceutical Solutions | 1 | 2016 | 14 | 0.140 |
Why?
| Neurosurgical Procedures | 1 | 2018 | 149 | 0.140 |
Why?
| Staphylococcal Infections | 1 | 2021 | 338 | 0.140 |
Why?
| Transplant Recipients | 2 | 2018 | 130 | 0.140 |
Why?
| Intensive Care Units, Neonatal | 1 | 2019 | 175 | 0.140 |
Why?
| Career Mobility | 1 | 2017 | 61 | 0.140 |
Why?
| Patient Readmission | 2 | 2019 | 608 | 0.140 |
Why?
| Chromatography, Reverse-Phase | 1 | 2016 | 26 | 0.130 |
Why?
| Enteral Nutrition | 2 | 2008 | 157 | 0.130 |
Why?
| Capsules | 1 | 2016 | 36 | 0.130 |
Why?
| Physical Therapy Modalities | 1 | 2019 | 265 | 0.130 |
Why?
| Solubility | 1 | 2016 | 221 | 0.130 |
Why?
| Opioid-Related Disorders | 1 | 2023 | 412 | 0.130 |
Why?
| Psychotropic Drugs | 1 | 2016 | 54 | 0.130 |
Why?
| Regression Analysis | 2 | 2016 | 932 | 0.130 |
Why?
| Drug Prescriptions | 1 | 2018 | 237 | 0.130 |
Why?
| Cholestyramine Resin | 1 | 2015 | 7 | 0.130 |
Why?
| Calibration | 1 | 2016 | 125 | 0.130 |
Why?
| Pharmacokinetics | 1 | 2015 | 25 | 0.120 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 297 | 0.120 |
Why?
| Ventricular Function, Left | 1 | 2018 | 469 | 0.120 |
Why?
| Isoxazoles | 1 | 2015 | 51 | 0.120 |
Why?
| Double-Blind Method | 4 | 2014 | 1643 | 0.120 |
Why?
| Internship, Nonmedical | 1 | 2015 | 16 | 0.120 |
Why?
| Societies, Pharmaceutical | 1 | 2015 | 25 | 0.120 |
Why?
| United States | 6 | 2019 | 12137 | 0.120 |
Why?
| Teaching | 1 | 2017 | 197 | 0.120 |
Why?
| Administration, Inhalation | 1 | 2016 | 633 | 0.120 |
Why?
| Prosthesis-Related Infections | 1 | 2015 | 69 | 0.120 |
Why?
| Pyridones | 1 | 2016 | 122 | 0.120 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 2014 | 25 | 0.120 |
Why?
| Anti-Ulcer Agents | 1 | 2014 | 15 | 0.120 |
Why?
| Histamine H2 Antagonists | 1 | 2014 | 26 | 0.120 |
Why?
| Peptic Ulcer | 1 | 2014 | 14 | 0.120 |
Why?
| Diltiazem | 1 | 2014 | 23 | 0.110 |
Why?
| Dabigatran | 1 | 2014 | 22 | 0.110 |
Why?
| beta-Alanine | 1 | 2014 | 17 | 0.110 |
Why?
| Seizures | 1 | 2017 | 335 | 0.110 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 405 | 0.110 |
Why?
| Immunoglobulin G | 1 | 2018 | 760 | 0.110 |
Why?
| Drug Dosage Calculations | 1 | 2014 | 21 | 0.110 |
Why?
| Thromboplastin | 1 | 2014 | 69 | 0.110 |
Why?
| Proton Pump Inhibitors | 1 | 2014 | 94 | 0.110 |
Why?
| Benzodiazepines | 1 | 2014 | 114 | 0.110 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2014 | 100 | 0.110 |
Why?
| Midazolam | 1 | 2013 | 43 | 0.110 |
Why?
| Guidelines as Topic | 1 | 2015 | 241 | 0.110 |
Why?
| Patient Acceptance of Health Care | 1 | 2019 | 679 | 0.110 |
Why?
| Medication Adherence | 1 | 2018 | 530 | 0.110 |
Why?
| Community-Acquired Infections | 1 | 2014 | 139 | 0.110 |
Why?
| Benzimidazoles | 1 | 2014 | 137 | 0.110 |
Why?
| Learning | 1 | 2017 | 344 | 0.110 |
Why?
| Antirheumatic Agents | 1 | 2015 | 253 | 0.110 |
Why?
| Motivation | 1 | 2017 | 486 | 0.100 |
Why?
| Antibiotic Prophylaxis | 1 | 2014 | 95 | 0.100 |
Why?
| Conscious Sedation | 1 | 2013 | 78 | 0.100 |
Why?
| Sirolimus | 1 | 2014 | 181 | 0.100 |
Why?
| Oxazolidinones | 1 | 2012 | 13 | 0.100 |
Why?
| Pyrazoles | 1 | 2016 | 361 | 0.100 |
Why?
| Colorado | 3 | 2017 | 4061 | 0.100 |
Why?
| Acetamides | 1 | 2012 | 25 | 0.100 |
Why?
| APACHE | 2 | 2010 | 58 | 0.100 |
Why?
| Lipids | 1 | 2016 | 558 | 0.100 |
Why?
| Coronary Artery Bypass | 1 | 2014 | 196 | 0.100 |
Why?
| Patient Selection | 1 | 2016 | 625 | 0.100 |
Why?
| Mental Recall | 1 | 2013 | 175 | 0.100 |
Why?
| Acute Disease | 1 | 2015 | 885 | 0.100 |
Why?
| Treatment Failure | 1 | 2013 | 323 | 0.100 |
Why?
| Fellowships and Scholarships | 1 | 2015 | 224 | 0.100 |
Why?
| Disease Progression | 2 | 2020 | 2364 | 0.100 |
Why?
| Metabolic Clearance Rate | 1 | 2012 | 103 | 0.100 |
Why?
| Research | 1 | 2015 | 387 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 195 | 0.090 |
Why?
| Metoclopramide | 2 | 2008 | 16 | 0.090 |
Why?
| Erythromycin | 2 | 2008 | 25 | 0.090 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2014 | 173 | 0.090 |
Why?
| Surgical Wound Infection | 1 | 2014 | 247 | 0.090 |
Why?
| Polymorphism, Genetic | 1 | 2014 | 603 | 0.090 |
Why?
| Neuromuscular Blockade | 1 | 2011 | 23 | 0.090 |
Why?
| Glucocorticoids | 1 | 2015 | 520 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2014 | 442 | 0.090 |
Why?
| Imipenem | 1 | 2010 | 16 | 0.090 |
Why?
| Genes, Regulator | 1 | 2010 | 33 | 0.090 |
Why?
| Drug Resistance | 1 | 2011 | 158 | 0.090 |
Why?
| Hypothermia, Induced | 1 | 2011 | 65 | 0.090 |
Why?
| Risk Assessment | 2 | 2016 | 2953 | 0.080 |
Why?
| Aortic Valve | 1 | 2014 | 391 | 0.080 |
Why?
| Pharmaceutical Vehicles | 1 | 2009 | 11 | 0.080 |
Why?
| Respiration, Artificial | 3 | 2020 | 536 | 0.080 |
Why?
| Propylene Glycol | 1 | 2009 | 9 | 0.080 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 305 | 0.080 |
Why?
| Protein C | 1 | 2010 | 43 | 0.080 |
Why?
| Biomedical Research | 1 | 2015 | 581 | 0.080 |
Why?
| Aging | 1 | 2019 | 1601 | 0.080 |
Why?
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 36 | 0.080 |
Why?
| Biomarkers | 2 | 2016 | 3389 | 0.080 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 1682 | 0.080 |
Why?
| Monitoring, Physiologic | 1 | 2010 | 247 | 0.080 |
Why?
| Certification | 1 | 2009 | 84 | 0.080 |
Why?
| Infant, Newborn | 1 | 2019 | 5032 | 0.080 |
Why?
| Acetaminophen | 2 | 2008 | 241 | 0.080 |
Why?
| Kidney Function Tests | 1 | 2008 | 139 | 0.070 |
Why?
| Liver Cirrhosis | 1 | 2009 | 226 | 0.070 |
Why?
| Lung Diseases | 1 | 2014 | 688 | 0.070 |
Why?
| Standard of Care | 2 | 2021 | 62 | 0.070 |
Why?
| Emergency Service, Hospital | 1 | 2018 | 1815 | 0.070 |
Why?
| Cost Control | 1 | 2007 | 38 | 0.070 |
Why?
| Databases as Topic | 1 | 2007 | 63 | 0.070 |
Why?
| Renal Dialysis | 1 | 2010 | 377 | 0.070 |
Why?
| Creatinine | 1 | 2008 | 434 | 0.070 |
Why?
| Propofol | 1 | 2007 | 43 | 0.070 |
Why?
| Fentanyl | 1 | 2007 | 67 | 0.070 |
Why?
| Analgesics, Non-Narcotic | 1 | 2008 | 117 | 0.070 |
Why?
| Practice Patterns, Physicians' | 1 | 2014 | 1176 | 0.070 |
Why?
| Half-Life | 1 | 2006 | 140 | 0.060 |
Why?
| Schools, Pharmacy | 2 | 2017 | 48 | 0.060 |
Why?
| Severity of Illness Index | 1 | 2013 | 2530 | 0.060 |
Why?
| Antidiuretic Agents | 1 | 2005 | 7 | 0.060 |
Why?
| Platelet Activation | 1 | 2005 | 65 | 0.060 |
Why?
| Chromatography, Liquid | 1 | 2007 | 339 | 0.060 |
Why?
| Platelet Aggregation | 1 | 2005 | 90 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2293 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 1378 | 0.060 |
Why?
| Animals | 2 | 2016 | 31162 | 0.060 |
Why?
| DNA | 1 | 2010 | 1331 | 0.050 |
Why?
| Penicillins | 1 | 2023 | 52 | 0.050 |
Why?
| Transcription Factors | 1 | 2010 | 1497 | 0.050 |
Why?
| Computer Simulation | 1 | 2006 | 858 | 0.050 |
Why?
| Minnesota | 1 | 2022 | 133 | 0.050 |
Why?
| Vasopressins | 1 | 2022 | 56 | 0.050 |
Why?
| Surveys and Questionnaires | 3 | 2021 | 4593 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 197 | 0.050 |
Why?
| Serum Albumin | 1 | 2022 | 137 | 0.050 |
Why?
| Hypertension, Pulmonary | 1 | 2012 | 1733 | 0.050 |
Why?
| Gender Identity | 1 | 2021 | 100 | 0.050 |
Why?
| Critical Care Outcomes | 1 | 2020 | 12 | 0.050 |
Why?
| Status Asthmaticus | 1 | 2020 | 10 | 0.050 |
Why?
| Polyphosphates | 1 | 2020 | 33 | 0.040 |
Why?
| Rifampin | 1 | 2021 | 68 | 0.040 |
Why?
| Sepsis | 2 | 2020 | 505 | 0.040 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 239 | 0.040 |
Why?
| Drug Synergism | 1 | 2021 | 312 | 0.040 |
Why?
| Methylene Blue | 1 | 2020 | 22 | 0.040 |
Why?
| Mutation | 1 | 2010 | 3313 | 0.040 |
Why?
| Pilot Projects | 2 | 2015 | 1356 | 0.040 |
Why?
| Hypersensitivity | 1 | 2023 | 251 | 0.040 |
Why?
| Bacteremia | 1 | 2021 | 157 | 0.040 |
Why?
| Sex Factors | 2 | 2018 | 1705 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2021 | 246 | 0.040 |
Why?
| Vascular Resistance | 1 | 2020 | 337 | 0.040 |
Why?
| Patient Satisfaction | 1 | 2022 | 570 | 0.040 |
Why?
| Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 578 | 0.040 |
Why?
| Hospital Charges | 1 | 2017 | 39 | 0.040 |
Why?
| Hospitals, Urban | 1 | 2018 | 128 | 0.040 |
Why?
| Bayes Theorem | 1 | 2019 | 325 | 0.040 |
Why?
| Venous Thrombosis | 1 | 2019 | 142 | 0.030 |
Why?
| Muscular Diseases | 1 | 2017 | 101 | 0.030 |
Why?
| Drug Interactions | 1 | 2018 | 332 | 0.030 |
Why?
| Insurance Coverage | 1 | 2018 | 199 | 0.030 |
Why?
| Problem-Based Learning | 1 | 2017 | 75 | 0.030 |
Why?
| Comorbidity | 1 | 2020 | 1443 | 0.030 |
Why?
| Pharmacology, Clinical | 1 | 2015 | 8 | 0.030 |
Why?
| Risk | 1 | 2018 | 807 | 0.030 |
Why?
| Education, Pharmacy | 1 | 2017 | 121 | 0.030 |
Why?
| Expert Testimony | 1 | 2015 | 36 | 0.030 |
Why?
| Educational Measurement | 1 | 2017 | 225 | 0.030 |
Why?
| Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.030 |
Why?
| Delphi Technique | 1 | 2015 | 157 | 0.030 |
Why?
| Checklist | 1 | 2015 | 85 | 0.030 |
Why?
| Cytochrome P-450 CYP2C8 | 1 | 2014 | 12 | 0.030 |
Why?
| Bradycardia | 1 | 2014 | 47 | 0.030 |
Why?
| Pharmacy Service, Hospital | 1 | 2015 | 83 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2014 | 4400 | 0.030 |
Why?
| Infusions, Parenteral | 1 | 2014 | 36 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 45 | 0.030 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 38 | 0.030 |
Why?
| Stress Disorders, Traumatic, Acute | 1 | 2013 | 6 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 61 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2014 | 61 | 0.030 |
Why?
| Tissue Distribution | 1 | 2014 | 280 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 332 | 0.030 |
Why?
| Demography | 1 | 2014 | 255 | 0.030 |
Why?
| Hypotension | 1 | 2014 | 115 | 0.030 |
Why?
| Cerebral Ventriculitis | 1 | 2012 | 3 | 0.030 |
Why?
| Linezolid | 1 | 2012 | 16 | 0.030 |
Why?
| Injections, Intraventricular | 1 | 2012 | 48 | 0.030 |
Why?
| Vancomycin Resistance | 1 | 2012 | 13 | 0.030 |
Why?
| Enterococcus faecium | 1 | 2012 | 10 | 0.030 |
Why?
| Healthcare Disparities | 1 | 2018 | 479 | 0.030 |
Why?
| Health Care Surveys | 1 | 2014 | 541 | 0.030 |
Why?
| Drainage | 1 | 2012 | 145 | 0.020 |
Why?
| Stress, Physiological | 1 | 2014 | 375 | 0.020 |
Why?
| Quality of Life | 1 | 2021 | 2335 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 633 | 0.020 |
Why?
| Contraindications | 1 | 2010 | 84 | 0.020 |
Why?
| Governing Board | 1 | 2009 | 7 | 0.020 |
Why?
| Multiple Organ Failure | 1 | 2010 | 114 | 0.020 |
Why?
| Genotype | 1 | 2014 | 1733 | 0.020 |
Why?
| Observer Variation | 1 | 2010 | 298 | 0.020 |
Why?
| Diagnostic Errors | 1 | 2010 | 150 | 0.020 |
Why?
| Specialization | 1 | 2009 | 112 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2010 | 315 | 0.020 |
Why?
| Intubation, Gastrointestinal | 1 | 2008 | 54 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2008 | 22 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 922 | 0.020 |
Why?
| Case-Control Studies | 1 | 2014 | 2993 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 970 | 0.020 |
Why?
| Anxiety | 1 | 2013 | 837 | 0.020 |
Why?
| Prognosis | 1 | 2014 | 3318 | 0.020 |
Why?
| Depression | 1 | 2013 | 1131 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2014 | 4384 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1783 | 0.010 |
Why?
| Age Factors | 1 | 2009 | 2875 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2010 | 2752 | 0.010 |
Why?
| Clinical Competence | 1 | 2009 | 882 | 0.010 |
Why?
| Physicians | 1 | 2010 | 765 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|